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maintained on their assigned dose frequency for darbepoetinRandomized trial of darbepoetin alfa for treatment of renal
alfa (once weekly and once every other week) and rHuEPOanemia at a reduced dose frequency compared with rHuEPO in
(once, twice and three times weekly). The safety profiles ofdialysis patients.
darbepoetin alfa and rHuEPO were similar, and no antibodiesBackground. Darbepoetin alfa is a glycoprotein with a three-
to either treatment were detected.fold longer terminal half-life than recombinant human eryth-
Conclusions. Darbepoetin alfa maintains hemoglobin as ef-ropoietin (rHuEPO). We aimed to determine whether darbe-
fectively as rHuEPO, but with a reduced dose frequency.poetin alfa is as effective and well tolerated as rHuEPO for
treating renal anemia in dialysis patients when administered
at a reduced dose frequency.
Methods. A total of 522 European and Australian hemodial-
Anemia is a frequent complication of chronic renalysis and peritoneal dialysis patients receiving stable rHuEPO
failure (CRF), caused predominantly by inadequate pro-therapy by either the intravenous (IV) or subcutaneous (SC)
route were randomized, open-label in a 1:2 ratio to continue duction of erythropoietin from the failing kidneys and
rHuEPO or to receive an equivalent dose of darbepoetin alfa inappropriately low circulating levels of erythropoietin
at a reduced dose frequency. Patients receiving rHuEPO once [1]. Replacement therapy with recombinant human ery-weekly changed to once every other week darbepoetin alfa, and
thropoietin (rHuEPO) has been used for the treatmentthose receiving rHuEPO two or three times weekly changed
to once-weekly darbepoetin alfa. The doses of rHuEPO and of renal and other anemias since its introduction into
darbepoetin alfa were titrated to maintain hemoglobin close clinical practice over 10 years ago [2–5]. During this time,
to the patient’s baseline level for up to 52 weeks. The primary rHuEPO has become widely accepted as an effective
endpoint was the change in hemoglobin between baseline and
and well-tolerated treatment, and its clinical benefits tothe evaluation period at weeks 25 to 32 of treatment.
patients with CRF are well documented [6]. rHuEPO isResults. The mean change in hemoglobin from baseline to the
evaluation period was similar in the darbepoetin alfa (0.03 administered by subcutaneous (SC) or intravenous (IV)
g/dL; SE 0.11) and rHuEPO (0.06 g/dL; SE 0.13) groups, injection and, because of its relatively short circulating
and the difference between the two treatments was 0.03 g/dL half-life, is recommended to be given two or three times(95% CI 0.16, 0.21). This was not a statistically significant or
per week [4, 6–8].clinically relevant difference, despite the reduced frequency of
Erythropoietin is a glycoprotein hormone compriseddarbepoetin alfa administration. At the end of the evaluation
period, 95% of patients had their hemoglobin successfully of approximately 60% protein and 40% carbohydrate.
The sialic acid-containing carbohydrate has been shown
to determine the serum half-life and in vivo activity of1 A complete list of study group members is in the Acknowledgments
section. erythropoietin [9]. Darbepoetin alfa (novel erythropoie-
sis stimulating protein; NESP) was designed by introduc-
Key words: darbepoetin alfa, novel erythropoiesis stimulating protein
ing five amino acid changes into the primary sequence(NESP), chronic renal failure, hemodialysis, peritoneal dialysis, anemia,
recombinant human erythropoietin. of rHuEPO to create two additional consensus N-linked
carbohydrate addition sites. Darbepoetin alfa has fiveReceived for publication September 19, 2001
N-linked carbohydrate chains, whereas rHuEPO has onlyand in revised form June 10, 2002
Accepted for publication July 8, 2002 three [9]. Because of its increased sialic acid-containing
carbohydrate content, darbepoetin alfa has a threefold 2002 by the International Society of Nephrology
2167
Vanrenterghem et al: Darbepoetin alfa treatment for renal anemia2168
Fig. 1. Study design.
longer terminal half-life in animal models [9] and in a 1:2 ratio to continue rHuEPO at their current dose,
humans [10] when compared with rHuEPO. This allows schedule and route of administration, or to change to
once weekly or once every other week dosing to treat darbepoetin alfa using the same route but at a reduced
anemia in CRF patients on dialysis [11]. We aimed to dose frequency (Fig. 1). The randomization was con-
determine whether darbepoetin alfa is as effective and ducted via a central computerized system, with unequal
well tolerated as rHuEPO for treating renal anemia in block sizes and stratification by center and frequency
dialysis patients, but at a reduced dose frequency. of rHuEPO dosing at study entry. Patients receiving
rHuEPO once weekly changed to darbepoetin alfa once
every other week, and patients receiving rHuEPO two
METHODS
or three times weekly changed to darbepoetin alfa once
Patients weekly. The initial dose of darbepoetin alfa for all pa-
tients was based on their rHuEPO dose at the time ofPatients were recruited from European and Australian
randomization, using a formula equating the proteindialysis units, and were required to be 18 years of age
mass of the two molecules (200 IU rHuEPO  1 gwith CRF, clinically stable and on hemodialysis (HD)
darbepoetin alfa). A period of 24 weeks (weeks 1 to 24)or peritoneal dialysis (PD) for at least six months. They
after the first dose of study drug was then used for dose-also had to be on stable rHuEPO (alfa or beta) therapy
titration and stabilization of hemoglobin. This was fol-given one, two, or three times weekly by the IV or SC
lowed by an eight-week evaluation period (weeks 25 toroute for at least three months, and to have a mean base-
32) for determining the primary efficacy endpoint, andline hemoglobin of 9.5 to 12.5 g/dL. To ensure adequate
a further 20 weeks (weeks 33 to 52) for additional safetyiron stores for supporting erythropoiesis, serum ferritin
information.had to be 100 g/L [6]. Patients were excluded from
In each treatment group, the dose of study drug wasthe study if they had hematological, inflammatory, infec-
adjusted to maintain individual patients’ hemoglobintious or other conditions that might interfere with the
within a target range of 1.0 to 1.5 g/dL of their base-erythropoietic response, or had red blood cell (RBC)
line hemoglobin and between 9 to 13 g/dL throughouttransfusions within one month before enrollment.
the 52-week study period. If a patient’s hemoglobin fellThe study was conducted in accordance with the Dec-
below the target range on two consecutive weekly as-laration of Helsinki and was approved by each institution’s
sessments, the dose of study drug was increased by 25%independent Research Ethics Committee. All patients
of the starting dose to a maximum of 100%. If thegave written informed consent before participation.
hemoglobin was still out of range, then the dose fre-
Study design quency was increased. If a patient’s hemoglobin increased
above the target range on two consecutive weekly assess-This was a multicenter, randomized, open-label com-
ments, the dose of study drug was decreased by 25% ofparative study designed to determine whether darbepoe-
the starting dose to a maximum of75%. If the hemoglo-tin alfa is as effective and well tolerated as rHuEPO
bin was still out of range, then the dose frequency waswhen administered IV or SC for treatment of anemia in
decreased. Dose frequency was adjusted incrementallydialysis patients.
as follows: 3 times weekly ⇔ 2 times weekly ⇔ onceAfter an initial four-week screening/baseline period,
patients receiving rHuEPO therapy were randomized in weekly ⇔ once every other week.
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Study medications
Darbepoetin alfa was supplied by Amgen Inc. (Thou-
sand Oaks, CA, USA). rHuEPO (alfa or beta) was ob-
tained from commercial sources and provided by the
pharmacy at each study center. To ensure adequate sup-
port of the erythropoietic response to study drug, IV
iron therapy was required to be administered to patients
with serum ferritin values100g/L. The IV iron dosing
regimen used for patients with serum ferritin values
100 g/L or100 g/L was determined by the individ-
ual center’s treatment policy.
Statistical analysis
The primary efficacy analysis compared the mean
change in hemoglobin between the screening/baseline
and evaluation periods for patients receiving darbepoe-
tin alfa and rHuEPO. To demonstrate non-inferiority,
the lower limit of the two-sided 95% confidence interval
(CI) for the difference in mean change in hemoglobin
on darbepoetin alfa and rHuEPO had to be above 0.5
g/dL. This was prospectively determined by the Study
Fig. 2. Patients included in the analysis. * Includes all randomized pa-Group to be the greatest clinically acceptable difference.
tients who received at least one dose of the study drug. ** Includes only
The 95% CI was calculated with and without adjustment patients who completed and had 6/8 hemoglobin assessments during
the evaluation period; received the allocated study drug according tofor covariates which might influence hemoglobin re-
protocol; had no change to dialysis modality or route of study drugsponse (study center, baseline rHuEPO dose, route and
administration; and received no red blood cell transfusions during weeks
frequency, dialysis modality, baseline hemoglobin). The 15–32 of study.
sample size of the study (495 patients) was selected using
a power of 90% (assessed at zero difference) and an
allocation ratio of 2:1 for darbepoetin alfa:rHuEPO, as- Within-subject variance in hemoglobin was calculated
suming a standard deviation for change in hemoglobin from the residuals of the linear regression model (that
of 1.44 and a drop-out rate of 30% over 12 months. is, mean squared error). All statistical analyses were per-
Using these criteria, the sample size was calculated to formed with the SAS software package (version 6.12;
be 330 darbepoetin alfa patients and 165 rHuEPO pa- SAS Institute, Cary, NC, USA).
tients [12].
A per-protocol (pP) analysis set was chosen for the
RESULTSmain analysis of the efficacy endpoints. A modified in-
tent-to-treat (mITT) analysis set was chosen for second- Patient characteristics
ary analysis, using several methods for imputing missing A total of 522 patients were randomized into the study,
values. Per-protocol analysis compares patients according of whom 347 were allocated to darbepoetin alfa and 175
to the treatment actually received and includes only remained on rHuEPO (Fig. 2). Patients were recruited
those patients who satisfy the protocol-specified criteria from 27 study sites in Europe and 4 in Australia between
(Fig. 2). This type of analysis is expected to increase any November 1997 and July 1998. A total of 519 patients
treatment difference, as it tends to remove uninformative received study drug and were included in the mITT anal-
data and is generally more conservative for non-inferior- ysis set (344 darbepoetin alfa, 175 rHuEPO) and the
ity studies [12]. The mITT analysis set and the safety safety analysis set (346 darbepoetin alfa, 173 rHuEPO).
analysis set included all randomized patients who re- Three hundred and thirty-six patients were included in
ceived the study drug. However, for the safety analysis the pP analysis set (224 darbepoetin alfa, 112 rHuEPO).
set, rHuEPO patients who inadvertently received at least The proportion of patients in the pP analysis set was the
one dose of darbepoetin alfa were included in the darbe- same for each treatment group (65% darbepoetin alfa,
poetin alfa group. Adverse event data are presented as 64% rHuEPO). Reasons for exclusion from the pP set
the proportion of patients experiencing an event one or were well balanced between treatment groups, suggesting
more times (subject incidence), and comparison between that there was no selection bias.
treatment groups was performed by calculating the odds Overall, 55% of the patients were male and 92% were
white. The mean age was 60.3 years (range 18 to 88) andratio (95% CI) for these proportions.
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Table 2. Patient baseline characteristicsTable 1. Patient demographics
Darbepoetin alfa rHuEPO Darbepoetin alfa rHuEPO
(N  347) (N  175)(N  347) (N  175)
Sex Cause of renal failure
Diabetes 58 (17%) 18 (10%)Male 188 (54%) 100 (57%)
Female 159 (46%) 75 (43%) Hypertension 27 (8%) 13 (7%)
Glomerulonephritis 66 (19%) 36 (21%)Race
White 316 (91%) 165 (94%) Polycystic kidney disease 30 (9%) 14 (8%)
Other/unknowna 166 (48%) 94 (54%)Asian 18 (5%) 5 (3%)
Black 11 (3%) 5 (3%) Dialysis modality
HD 318 (92%) 163 (93%)Other 2 (1%) 0 (0%)
Agea years 60.1 (18–88) 60.9 (22–87) PD 29 (8%) 12 (7%)
Time since first dialysisaWeighta kg 68.4 (31.5–123.0) 69.0 (38.0–184.0)
months 32.0 (18.5–55.5) 36.7 (19.3–63.6)a Mean (range)
rHuEPO dosea IU/week 6000 (4000–9000) 6000 (4000–9000)
Route of rHuEPO
administration
IV 134 (39%) 73 (42%)
SC 213 (61%) 102 (58%)the mean weight was 69 kg (range 32 to 184). The most
Frequency of rHuEPO
common single causes of CRF were glomerulonephritis Once per week 66 (19%) 35 (20%)
Twice per week 118 (34%) 59 (34%)and diabetes mellitus. The median time since initiation of
Three times per week 163 (47%) 81 (46%)dialysis was 34 months (quartiles 18.8 to 59.6), with 92%
Baseline hemoglobin levelb
of patients receiving hemodialysis (HD) and 8% perito- g/dL 11.0 (9.5–12.5) 11.0 (9.5–12.5)
Serum ferritina lg/L 305.8 (199.3–517.4) 288.7 (184.6–487.9)neal dialysis (PD). The median weekly rHuEPO dose at
baseline was 6000 IU/week (quartiles 4000 to 6000) and a Unknown category includes ‘suspected’ unconfirmed causes
b Median (quartiles)82% of patients were receiving rHuEPO alpha. rHuEPO c Mean (range)
injection frequencies were once (19%), twice (34%) and
thrice weekly (47%), and mostly by the SC route (60%).
The mean baseline hemoglobin was 11.0 g/dL (range 9.5
fore the adjustment for covariates. The difference in theto 12.5). Demographic and baseline characteristics of the
mean change in hemoglobin between these two groupstwo treatment groups were well balanced (Tables 1 and
was 0.05 g/dL (95% CI 0.14, 0.24). After adjusting for2), and were representative of the CRF population from
covariates, the mean change in hemoglobin from baselinewhich they were derived. Transferrin saturation, C-reac-
to the evaluation period also was similar in the darbepoe-tive protein and dialysis membrane data were not col-
tin alfa (0.03 g/dL; SE  0.11) and rHuEPO (0.06lected in the study. Characteristics of the pP, mITT, and
g/dL; SE  0.13) groups. The difference in the meansafety analysis sets were similar and also were well bal-
anced between treatment groups. change in hemoglobin between these two groups was
The overall exposure to study drug in weeks (mean; 0.03 g/dL (95% CI 0.16, 0.21). The lower limit of the
range) was similar in the darbepoetin alfa (44; 0 to 52) two-sided 95% CI was therefore above the pre-specified
and rHuEPO (46; 2 to 52) treatment groups. One hun- non-inferiority margin of –0.5 g/dL whether adjusted
dred and thirty-three patients (25%) did not complete (0.16) or unadjusted (0.14) for covariates, demon-
the 52 weeks of study. The most common reasons were strating that darbepoetin alfa was as effective as rHuEPO
death, kidney transplant and withdrawal requested. The in maintaining the mean hemoglobin in this group of
rates of discontinuation were similar between the treat- patients. The robustness of the pP analysis was confirmed
ment groups during the dose-titration (12% darbepoetin by analyzing the primary endpoint using the mITT analy-
alfa, 10% rHuEPO) and evaluation (4% darbepoetin alfa, sis set. The lower limit of the 95% CI was similar to the
3% rHuEPO) periods. However, in the maintenance pe- pP analysis set whether adjusted (0.14) or unadjusted
riod the difference was 6% (12% darbepoetin alfa, 6% (0.13) for covariates, and was well above the pre-speci-
rHuEPO), and this is discussed further in the analysis fied non-inferiority margin of –0.5 g/dL.
of safety. Since the study enrolled dialysis patients receiving dif-
fering treatment practices, the primary efficacy endpoint
Efficacy evaluation was analyzed by sub-groups. The most important of these
were route of study drug administration (SC/IV) andPrimary analysis. The mean weekly hemoglobin val-
ues for the darbepoetin alfa and rHuEPO groups were dialysis modality (HD/PD). Since PD patients receive
rHuEPO (or darbepoetin alfa) solely by the SC route,very similar throughout the study (Fig. 3). The mean
change in hemoglobin from baseline to the evaluation three sub-groups were evaluated: the IV and SC routes
in HD patients and the SC route in PD patients. Theperiod was similar in the darbepoetin alfa (0.05 g/dL;
SD 0.80) and rHuEPO (0.00 g/dL; SD 0.87) groups be- lower limit of the 95% confidence interval was above
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Fig. 3. Mean ( 2 SD) hemoglobin over time.
Symbols are: () darbepoetin alfa (N347); ()
recombinant human erythropoietin (rHuEPO;
N 175). Whiskers denote standard deviation.
the protocol specified non-inferiority margin in each of
these sub-groups (0.05, 0.42, 0.31, respectively),
demonstrating that darbepoetin alfa is as effective as
rHuEPO. Additionally, when the primary endpoint was
analyzed for other sub-groups (study center, baseline
rHuEPO dose and frequency, baseline hemoglobin, age,
sex and race), the results also were consistent with the
main analyses.
Secondary analyses. A number of endpoints explored
whether less frequent dosing with darbepoetin alfa could
result in more unstable or more variable hemoglobin con-
centrations. These were: the proportion of patients with
“unstable hemoglobin” (defined as hemoglobin values
necessitating a dose change), within-subject variance of
hemoglobin, and the proportion of patients with hemo-
globin in the target (–1.0 to 1.5 g/dL of baseline and
Fig. 4. Mean (95% CI) dose of study drug by route of administration.between 9 to 13 g/dL) and therapeutic (9 to 13 g/dL)
Symbols are: () IV dosing; () SC dosing.ranges during the evaluation period. The ratios (95%
CI) between the darbepoetin alfa and rHuEPO groups
for each of these endpoints were calculated as 0.794
was similar in the two treatment groups during each(0.476, 1.325), 1.030 (0.855, 1.242), 1.036 (0993, 1.081),
week of the study. Dosing was further evaluated by routeand 1.018 (0.929, 1.116), respectively. In all cases the 95%
of administration in patients who received darbepoetinCI included 1.0, indicating no significant difference be-
alfa and rHuEPO during weeks 21 to 24, 33 to 36 andtween the two treatment groups. These results demon-
49 to 52 of the study, when patients had been titrated tostrate that darbepoetin alfa does not increase hemoglobin
a stable hemoglobin level (Fig. 4). The ratio (95% CI)
variability compared with rHuEPO, despite the reduced of SC to IV doses during these three periods of the study
frequency of dosing. was 1.00 (0.84, 1.18), 1.05 (0.87, 1.28) and 1.11 (0.88, 1.39)
Dosing during the evaluation period was similar to for darbepoetin alfa. These ratios were not significantly
baseline and was also similar between treatment groups. different from 1.0, suggesting similar dose requirements
The mean (95% CI) treatment difference, when the dos- for the SC and IV route. In contrast, the ratio (95% CI)
ing units of rHuEPO were converted to the dosing units of SC to IV doses was 0.81 (0.65, 1.02), 0.76 (0.61, 0.96)
of darbepoetin alfa, was0.40 g/week (5.9, 5.2). Addi- and 0.77 (0.60, 0.99) for rHuEPO, and the second and
third of these ratios were significantly different from 1.0tionally, the proportion of patients requiring dose changes
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Fig. 5. Odds ratio (95% CI) between darbepoetin alfa and rHuEPO for adverse events occurring with a frequency of 10% in either treatment
group.
(P  0.05). The average ratio for the three periods was Safety
0.78, suggesting that the rHuEPO dose requirements were A similar proportion of patients on darbepoetin alfa
22% lower by the SC route compared with the IV route. (96%) and rHuEPO (95%) experienced at least one ad-
The frequency of study drug administration during verse event. The odds ratio (95% CI) between darbepoe-
the evaluation period was evaluated for each treatment tin alfa and rHuEPO for those events occurring with a
group. Ninety-seven percent (178/183) of patients whose frequency of 10% in either treatment group are pre-
baseline rHuEPO dose frequency was two or three times sented in Figure 5. There was no difference in adverse
weekly were successfully maintained on darbepoetin alfa event reporting between darbepoetin alfa and rHuEPO,
given once weekly or less. Ninety-five percent (39/41) of with the exception of pruritus. The three most commonly
patients whose baseline rHuEPO dose frequency was reported events were hypotension (39% darbepoetin alfa,
once-weekly were successfully maintained on darbepoe-
38% rHuEPO), myalgia (34% darbepoetin alfa, 36%tin alfa given once every other week. Ninety-five percent
rHuEPO) and hypertension (30% darbepoetin alfa, 28%(20/21), 98% (39/40) and 98% (50/51) of the rHuEPO
rHuEPO), and the largest between group differencestreated patients were successfully maintained on the same
were for pruritus (14% darbepoetin alfa, 5% rHuEPO)dose frequency as at baseline (1, 2 or 3 times weekly, re-
and back pain (10% darbepoetin alfa, 16% rHuEPO).spectively). Dosing frequency during evaluation also was
Most of these events were attributed to concurrent medi-analyzed by sub-group, and the results of these analyses
cal conditions and were consistent with events expectedwere consistent with the main analysis. Weekly serum
in this patient population.trough concentrations of darbepoetin alfa and rHuEPO
Six adverse events were prospectively defined to bewere determined by enzyme-linked immunosorbent as-
of particular interest because of previous concerns withsay (ELISA) over the 52 weeks of the study. There was
increasing hemoglobin in dialysis patients. Analysis ofminimal accumulation of either drug when analyzed
these six events showed no significant difference (P overall and within patient sub-groups. At weeks 12, 24,
0.682) in incidence between treatment groups: hyper-36 and 52, the mean serum concentration was 0.43, 0.48,
tension (30% darbepoetin alfa, 28% rHuEPO), cerebro-0.54 and 0.49 ng/mL for darbepoetin alfa and 17.9, 19.9,
18.5 and 19.8 mU/mL for rHuEPO. vascular disorder (2% darbepoetin alfa, 1% rHuEPO),
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myocardial infarction (1% darbepoetin alfa, 2% rHuEPO), study drug. There was no difference in the proportion
convulsions (2% darbepoetin alfa, 2% rHuEPO), vascular of patients requiring transfusions in the darbepoetin alfa
access thrombosis (10% darbepoetin alfa, 9% rHuEPO), group (4%) compared with the rHuEPO group (5%).
and transient ischemic attack (0% darbepoetin alfa, 1% Vital signs were monitored throughout the study, and
rHuEPO). no changes in mean blood pressure or heart rate were
Adverse events that were commonly (1%, 	10%) observed in either treatment group. The use of antihy-
reported by the investigators to be at least possibly re- pertensive medications also was similar in each treatment
lated to study drug were hypertension, injection site pain, group. Screening for darbepoetin alfa and rHuEPO anti-
headache, vascular access thrombosis, anemia and fa- bodies was performed by radioimmune precipitation as-
tigue. Injection site pain following subcutaneous admin- say before the first dose of study drug and at three-
istration of darbepoetin alfa was reported more fre- month intervals thereafter, and all were negative.
quently than with rHuEPO. This discomfort was generally
mild and transient in nature and occurred predominantly
DISCUSSIONafter the first injection. All other treatment related ad-
verse events were reported at a level of 	1% in both The results of this randomized, comparative study
treatment groups, including pruritus (1% darbepoetin demonstrate that darbepoetin alfa is as effective as
alfa, 0% rHuEPO). The majority were mild to moderate rHuEPO for treating renal anemia in dialysis patients,
in severity and were consistent with the comorbidities but at a reduced dose frequency. When analyzed by
expected in this patient population. route of study drug administration (IV/SC) and dialysis
There were 52 deaths during the study and within 28 modality (HD/PD), darbepoetin alfa was similarly dem-
days after the last dose of study drug or last assessment, onstrated to be as effective as rHuEPO. Switching from
whichever was latest. A higher proportion of patients rHuEPO to darbepoetin alfa was accomplished without
died in the darbepoetin alfa treatment group (41/346; an increased risk of unstable hemoglobin concentrations.
12%) compared with the rHuEPO group (11/173; 6%), Darbepoetin alfa-treated patients successfully maintained
although this difference was not statistically significant hemoglobin within the target and therapeutic ranges dur-
(P  0.062). Deaths resulted from co-morbid conditions ing the study, with a similar number of dose adjustments
and no apparent relationship to study drug could be as the rHuEPO-treated patients. The results were consis-
determined. All deaths were reported by the study inves- tent within patient sub-groups, and were robust to the
tigators as unrelated to study drug. As the majority of type of analysis methods.
patients who received darbepoetin alfa carried on treat- The mean dose of study drug during the evaluation
ment in a long-term protocol after this study, a further period was similar in both treatment groups and also
survival follow-up was performed on all randomized pa- was similar to baseline, indicating that the initial protein
tients who received study drug (darbepoetin alfa and mass substitution formula was appropriate for providing
rHuEPO). After a mean follow-up of two years, the
patients with a therapeutic starting dose of darbepoetin
mortality rate was similar in both treatment groups (25%
alfa. However, as with rHuEPO therapy [13–14], theredarbepoetin alfa vs. 21% rHuEPO). When the mortality
was a large inter-patient variability in dose requirements,rates for the total follow-up period were annualized, the
and dose titration may be required to maintain the rec-rate was 13% for darbepoetin alfa and 11% for rHuEPO.
ommended hemoglobin target range. When dosing of dar-There was no statistically significant difference between
bepoetin alfa and rHuEPO were analyzed by route ofthe survival in the two treatment groups (P  0.212).
administration there was no difference in IV and SCSerum ferritin concentrations were similar in the dar-
dose requirements for darbepoetin alfa, but an averagebepoetin alfa and rHuEPO treatment groups throughout
22% lower dose requirement for SC rHuEPO comparedthe study. At weeks 12, 24, 36 and 52, mean serum ferritin
with the IV route. The fact that no such dosing differencewas 394, 382, 353 and 391 g/L for darbepoetin alfa and
was observed with darbepoetin alfa might be explained367, 385, 362 and 375 g/L for rHuEPO. Most patients
by the longer terminal half-life of the molecule comparedhad serum ferritin concentration 100 g/L at baseline
with rHuEPO, particularly when administered by the IV(99%) and at the end of study (95%). The proportion
route. Results of a double-blind, randomized pharmaco-of patients receiving intravenous iron supplementation
kinetic study indicated that the terminal half-life of dar-was the same in both treatment groups (87%), and the
bepoetin alfa was 25.3 hours by the IV route and 48.8mean weekly patient-dose of intravenous iron was simi-
hours by the SC route. In contrast, the terminal half-lifelar in the darbepoetin alfa (136 mg) and rHuEPO (145
of rHuEPO was 8.5 hours by the IV route and frommg) treatment groups.
historical data was 16 to 24 hours by the SC route [10].Clinical laboratory evaluation of hematology, bio-
Therefore, the ratio of the IV:SC half-life is higher forchemistry and coagulation throughout the study showed
no unexpected changes that could be attributable to the darbepoetin alfa than for rHuEPO, resulting in serum
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concentrations above the threshold for stimulation of ery- ments for darbepoetin alfa may allow European and
Australian hemodialysis patients currently receiving SCthropoiesis for proportionately longer by the IV route.
The optimum frequency of rHuEPO dosing in CRF injections to switch to IV dosing. Further studies will be
needed to confirm this finding in patients in other geo-patients has been addressed in a number of clinical studies,
and controversial results exist regarding the efficacy of graphic regions. There also is evidence that a reduced
frequency of administration is possible in patients withonce weekly rHuEPO dosing compared with two and three
times weekly dosing. While a recent randomized study chronic renal insufficiency (who are not yet receiving
dialysis) [22].found no difference in the weekly SC dose of rHuEPO
beta when administration frequency was reduced to once
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